From the specific vantage point of the interventional cardiologist, based on the results of the ODYSSEY Outcomes Trial, which patients who have undergone PCI do you believe are the best candidates for PCSK9 therapy?

From the specific vantage point of the interventional cardiologist, based on the results of the ODYSSEY Outcomes Trial, which patients who have undergone PCI do you believe are the best candidates for PCSK9 therapy?

From the specific vantage point of the interventional cardiologist, based on the results of the ODYSSEY Outcomes Trial, which patients who have undergone PCI do you believe are the best candidates for PCSK9 therapy?


Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Medical Cardiology, Interventional Cardiology, Lipid Medicine, Atherosclerosis and Diabetes Specialist's Perspective

Presenter

Phillipe Steg, MD

Phillipe Steg, MD

Professor of Cardiology Université Paris – Diderot, Sorbonne-Paris Cité Professor, National Heart and Lung Institute Imperial College, London, UK Director, Coronary Care Unit Hôpital Bichat Paris, France